Greenleaf Trust Has $1.25 Million Position in Zoetis Inc. $ZTS

Greenleaf Trust trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 17.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,014 shares of the company’s stock after selling 1,675 shares during the period. Greenleaf Trust’s holdings in Zoetis were worth $1,250,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis in the first quarter worth approximately $25,000. 1248 Management LLC purchased a new position in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter worth $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, ORG Partners LLC lifted its position in shares of Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.4%

Shares of Zoetis stock opened at $146.87 on Thursday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The stock’s 50-day simple moving average is $150.02 and its 200 day simple moving average is $155.39. The stock has a market capitalization of $65.09 billion, a P/E ratio of 25.28, a P/E/G ratio of 2.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the previous year, the business posted $1.56 EPS. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ZTS shares. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.